KR102514914B1 - 카르바졸 유도체 - Google Patents

카르바졸 유도체 Download PDF

Info

Publication number
KR102514914B1
KR102514914B1 KR1020177013606A KR20177013606A KR102514914B1 KR 102514914 B1 KR102514914 B1 KR 102514914B1 KR 1020177013606 A KR1020177013606 A KR 1020177013606A KR 20177013606 A KR20177013606 A KR 20177013606A KR 102514914 B1 KR102514914 B1 KR 102514914B1
Authority
KR
South Korea
Prior art keywords
carbazole
carboxamide
fluoro
tetrahydro
hydroxypropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177013606A
Other languages
English (en)
Korean (ko)
Other versions
KR20170075756A (ko
Inventor
살림 아마드
더글러스 쥐. 배트
칭제 류
존 이. 마코르
조셉 에이. 티노
스콧 헌터 와터슨
사티쉬 케사반 나이르
타룬 쿠마르 마이샬
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102514914(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20170075756A publication Critical patent/KR20170075756A/ko
Application granted granted Critical
Publication of KR102514914B1 publication Critical patent/KR102514914B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020177013606A 2014-10-24 2015-10-23 카르바졸 유도체 Active KR102514914B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
US62/068,234 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (2)

Publication Number Publication Date
KR20170075756A KR20170075756A (ko) 2017-07-03
KR102514914B1 true KR102514914B1 (ko) 2023-03-27

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177013606A Active KR102514914B1 (ko) 2014-10-24 2015-10-23 카르바졸 유도체

Country Status (34)

Country Link
US (3) US10266491B2 (enExample)
EP (1) EP3209651B9 (enExample)
JP (1) JP6599983B2 (enExample)
KR (1) KR102514914B1 (enExample)
CN (1) CN107074804B (enExample)
AR (1) AR102427A1 (enExample)
AU (1) AU2015335703B2 (enExample)
BR (1) BR112017007545A2 (enExample)
CA (1) CA2965523A1 (enExample)
CL (1) CL2017001001A1 (enExample)
CO (1) CO2017004517A2 (enExample)
CY (1) CY1122549T1 (enExample)
DK (1) DK3209651T3 (enExample)
EA (1) EA032361B1 (enExample)
ES (1) ES2761903T3 (enExample)
HR (1) HRP20192197T2 (enExample)
HU (1) HUE048321T2 (enExample)
IL (1) IL251798B (enExample)
LT (1) LT3209651T (enExample)
MA (1) MA40302B1 (enExample)
ME (1) ME03754B (enExample)
MX (1) MX374724B (enExample)
MY (1) MY190568A (enExample)
PE (1) PE20171239A1 (enExample)
PH (1) PH12017500724B1 (enExample)
PL (1) PL3209651T3 (enExample)
PT (1) PT3209651T (enExample)
RS (1) RS59707B1 (enExample)
SG (2) SG11201703187PA (enExample)
SI (1) SI3209651T1 (enExample)
SM (1) SMT202000035T1 (enExample)
TN (1) TN2017000158A1 (enExample)
TW (1) TWI676618B (enExample)
WO (1) WO2016065236A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
HRP20210320T1 (hr) 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Spojevi heteroarila za liječenje oftalmičkih bolesti
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
WO2021067657A1 (en) * 2019-10-04 2021-04-08 Bristol-Myers Squibb Company Substituted carbazole compounds
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
AU2021253584A1 (en) * 2020-04-10 2022-11-17 Gb005, Inc. Kinase inhibitors
WO2021247748A1 (en) * 2020-06-02 2021-12-09 Gb005, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
WO2024010784A1 (en) * 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
CN120530096A (zh) * 2022-09-29 2025-08-22 维维迪昂疗法有限公司 作为keap1调节剂的n-丙烯酰吗啉衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[１,２-ａ]피라진-８-일아민, 그의 제조 방법및 용도
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) * 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
SG174810A1 (en) 2006-09-11 2011-10-28 Matrix Lab Ltd Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011512354A (ja) 2008-02-14 2011-04-21 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経機能障害を検知するための新規の造影剤
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011524893A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
CN102325753B (zh) * 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
KR101585753B1 (ko) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
AU2013207972B2 (en) 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
JP6139690B2 (ja) 2012-10-26 2017-05-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルートンチロシンキナーゼの阻害剤
TWI648272B (zh) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
US9714234B2 (en) * 2013-06-25 2017-07-25 Bristol-Myers Squibb Company Carbazole carboxamide compounds
DK3461821T3 (da) 2014-10-24 2020-08-17 Bristol Myers Squibb Co Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liu, Q. 등, Bioorganic & Medicinal Chemistry Letters, 2018, 제28권, 페이지 3080-3084

Also Published As

Publication number Publication date
IL251798B (en) 2020-08-31
CL2017001001A1 (es) 2017-11-24
HRP20192197T1 (hr) 2020-03-06
CN107074804A (zh) 2017-08-18
PT3209651T (pt) 2019-12-30
LT3209651T (lt) 2020-01-10
TN2017000158A1 (en) 2018-10-19
IL251798A0 (en) 2017-06-29
MA40302B1 (fr) 2018-10-31
ME03754B (me) 2021-04-20
HRP20192197T2 (hr) 2020-11-13
DK3209651T3 (da) 2020-02-03
EP3209651B1 (en) 2019-10-23
CY1122549T1 (el) 2021-01-27
TWI676618B (zh) 2019-11-11
SG10201903619YA (en) 2019-05-30
JP6599983B2 (ja) 2019-10-30
AU2015335703A1 (en) 2017-06-08
CA2965523A1 (en) 2016-04-28
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
AU2015335703B2 (en) 2020-05-21
EA201790745A1 (ru) 2017-08-31
MY190568A (en) 2022-04-27
SI3209651T1 (sl) 2019-12-31
HRP20192197T8 (hr) 2020-04-03
EP3209651B9 (en) 2020-05-20
WO2016065236A1 (en) 2016-04-28
SG11201703187PA (en) 2017-05-30
MA40302A1 (fr) 2018-05-31
US20200255377A1 (en) 2020-08-13
CO2017004517A2 (es) 2017-08-31
TW201629014A (zh) 2016-08-16
BR112017007545A2 (pt) 2017-12-19
MX374724B (es) 2025-03-06
CN107074804B (zh) 2020-02-18
KR20170075756A (ko) 2017-07-03
US10676434B2 (en) 2020-06-09
PE20171239A1 (es) 2017-08-24
PH12017500724A1 (en) 2017-10-09
PH12017500724B1 (en) 2023-07-05
PL3209651T3 (pl) 2020-03-31
US20170362176A1 (en) 2017-12-21
JP2017535536A (ja) 2017-11-30
HUE048321T2 (hu) 2020-07-28
AR102427A1 (es) 2017-03-01
US10266491B2 (en) 2019-04-23
EP3209651A1 (en) 2017-08-30
RS59707B1 (sr) 2020-01-31
SMT202000035T1 (it) 2020-03-13
US20190225583A1 (en) 2019-07-25
ES2761903T3 (es) 2020-05-21
EA032361B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
KR102514914B1 (ko) 카르바졸 유도체
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
KR102519536B1 (ko) 트리시클릭 회전장애이성질체 화합물
HK1238642B (en) Carbazole derivatives
HK1238642A1 (en) Carbazole derivatives
NZ754113B2 (en) Indole carboxamide compounds useful as kinase inhibitors
NZ731946B2 (en) Indole carboxamide compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201023

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220614

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230323

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230323

End annual number: 3

Start annual number: 1

PG1601 Publication of registration